HOMA-IR normalized measure of insulin resistance HOMA-%B normalized measure of beta-cell function IDMC Independent Data Monitoring Committee IR immediate-release ITT intent-to-treat LAI long-acting injectable LDL low-density lipoprotein MA maintenance MedDRA Medical Dictionary for Regulatory Activities mg eq. milligram equivalents mITT Modified intent-to-treat NMS neuroleptic malignant syndrome OL open-label P-gp P-glycoprotein PANSS positive and negative syndrome trial PK pharmacokinetic(s) PP1M paliperidone palmitate 1-month formulation PP3M paliperidone palmitate 3-month formulation linear derived method for calculation of heart rate-corrected QT interval QTcB Bazett method for calculation of corrected QT interval QTcF Fridericia method for calculation of corrected QT interval SAE serious adverse event SAS Simpson Angus rating scale SBP systolic blood pressure SCS summary of clinical safety SOC system class
HOMA-IR normalized measure of insulin resistance HOMA-%B normalized measure of beta-cell function IDMC Independent Data Monitoring Committee IR immediate-release ITT intent-to-treat LAI long-acting injectable LDL low-density lipoprotein MA maintenance MedDRA Medical Dictionary for Regulatory Activities mg eq. milligram equivalents mITT Modified intent-to-treat NMS neuroleptic malignant syndrome OL open-label P-gp P-glycoprotein PANSS positive and negative syndrome PK pharmacokinetic(s) PP1M paliperidone palmitate 1-month formulation PP3M paliperidone palmitate 3-month formulation linear derived method for calculation of heart rate-corrected QT interval QTcB Bazett method for calculation of corrected QT interval QTcF Fridericia method for calculation of corrected QT interval SAE serious adverse event SAS Simpson Angus rating scale SBP systolic blood pressure SCS summary of clinical safety SOC system class trial
auspar-paliperidone-palmitate-171013-cer.docx